A stunning wave of investment is rushing into the battle against antibiotic-resistant diseases: the Ellison Institute has granted £118 million to Oxford University’s Vaccine Group to kick off a five-year, AI-powered vaccine initiative targeting pathogens like E. coli, pneumococcus, and staph—organisms that have stubbornly evaded traditional vaccination efforts. This is one of Oxford’s most significant










